Patrick Daly

DocwireNews

A majority of female patients with inherited bleeding disorders, including von Willebrand Disease (VWD), hemophilia A, and hemophilia B, experienced bleeding symptoms that may call for the initiation of prophylaxis with factor and non-factor replacement therapy, particularly with more than one or two bleeding events per year, according to a retrospective single-center database analysis.Additionally, during a presentation at the 65th American Society of Hematology Annual Meeting &amp; Exhibition in San Diego, California, lead author, Daniel Barnett, MD, from the Banner University Medical Center in Phoenix, Arizona, suggested that &ldquo;heavy menstrual bleeding, joint bleeding, joint pain, [and] gastrointestinal and genitourinary bleeding are reported in this patient population as reasons to start prophylaxis with hemostatic agents.&rdquo;The analysis reviewed 101 female patients from the Banner MD Anderson Cancer bleeding disorder database, of whom 64 had a diagnosis of hemophilia A, hemophilia B, or VWD. Researchers reviewed the type of treatment, reason for treatment initiation, and type of administration.Overall, 13 of 17 (76%) patients with hemophilia A were receiving prophylaxis with factor replacement or emicizumab. The most common reasons for initiating prophylaxis were joint pain and bleeding in six patients and menorrhagia in three patients. Among the four patients with hemophilia B, two (50%) were receiving factor replacement, with rectal bleeding and menorrhagia recorded as reasons for starting prophylaxis.In the VWD group, 24 of 43 (56%) patients were receiving prophylaxis with one or more of the following: factor replacement, desmopressin, or antifibrinolytic replacement. The most common reason for initiating treatment was menorrhagia in 13 patients followed by joint bleeding in four patients. Additional reasons including trauma, mucocutaneous, urinary tract, and pregnancy bleeding.Notably, patients with VWD were much more likely to require central intravenous treatment administration via a chest portacath (n=14; 33%) and were more likely to have received their diagnosis prior to age 18 years (n=16; 37%).In closing, Dr. Barnett noted, &ldquo;Once factor replacement is started, patients are pleased with the change in their health status after initiation of treatment and continue to be compliant with treatment recommendations although they may have difficulty in administering those treatments.&rdquo;ReferenceBarnett D, Nance D. a retrospective analysis and characterization of female patients with bleeding disorders hemophilia B, hemophilia B and von Willebrand&rsquo;s disease and their treatment type at Banner MD Anderson Cancer Center. Abstract #1254. Presented at the 65th ASH Annual Meeting &amp; Exposition; December 9-12, 2023; San Diego, California.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Assessing Reasons for Treatment and Treatment Type in Females with Bleeding Disorders

Hemophilia

Women with inherited bleeding disorders may need prophylaxis.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe